Theratechnologies Inc Quick Ratio (THTX) starting from the fourth quarter 2024 to fourth quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Theratechnologies Inc   (NASDAQ: THTX)

Theratechnologies Inc 's Quick Ratio

THTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Theratechnologies Inc 's Cash & cash equivalent grew by 269.52 % in the Q4 2024 sequentially, while Current Liabilities decreased, this led to improvement in Theratechnologies Inc 's Quick Ratio to 0.79, above Theratechnologies Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 464 other companies have achieved higher Quick Ratio than Theratechnologies Inc in fourth quarter 2024. While Quick Ratio total ranking in the fourth quarter 2024 has deteriorated compared to the prior quarter from 427 to 3786.

Explain Quick Ratio?
How much Cash & cash equivalents THTX´s has?
What are THTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

THTX Quick Ratio (Nov 30 2024)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Nov 30 2023)
Q4
Y / Y Current Liabilities Change -66.72 % -13.44 % -13.44 % -13.44 % 102.24 %
Y / Y Cash & cash equivalent Change -68.04 % -82.7 % -82.7 % -82.7 % 185.86 %
Quick Ratio MRQ 0.79 0.14 0.14 0.14 0.82
THTX's Total Ranking # 3786 # 427 # # #
Seq. Current Liabilities Change -32.48 % 0 % 0 % -50.71 % 75.61 %
Seq. Cash & cash equivalent Change 269.52 % 0 % 0 % -91.35 % 100 %



Quick Ratio fourth quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 465
Healthcare Sector # 917
Overall Market # 3786


Quick Ratio Statistics
High Average Low
0.77 0.55 0.14
(Nov 30 2019)   (Nov 30 2024)




Financial Statements
Theratechnologies Inc 's Current Liabilities $ 28 Millions Visit THTX's Balance sheet
Theratechnologies Inc 's Cash & cash equivalent $ 22 Millions Visit THTX's Balance sheet
Source of THTX's Sales Visit THTX's Sales by Geography


Cumulative Theratechnologies Inc 's Quick Ratio

THTX's Quick Ratio for the trailling 12 Months

THTX Quick Ratio

 (Nov 30 2024)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Nov 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth -33.11 % 12.53 % 20.56 % 33.65 % 21.87 %
Y / Y Cash & cash equivalent TTM Growth -76.83 % -31.91 % 1.46 % 56.21 % 49.14 %
Quick Ratio TTM 0.26 0.42 0.54 0.65 0.76
Total Ranking TTM # 3713 # 3980 # # #
Seq. Current Liabilities TTM Growth -26.91 % -2.99 % -2.91 % -2.83 % 22.95 %
Seq. Cash & cash equivalent TTM Growth -54.02 % -24.72 % -19.82 % -16.54 % 35.15 %

Quick ratio ranking by company, industry and sector >> Back to THTX Financial Strength Comparisons >> Go to Compare THTX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in THTX's Current Liabilities to $27.64 millions, cumulative Quick Ratio to 0.26 below the THTX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 459 other companies have achieved higher Quick Ratio than Theratechnologies Inc . While Quick Ratio overall ranking has improved so far to 3713, from total ranking during the twelve months ending third quarter 2024 at 3980.

Explain Quick Ratio?
How much Cash & cash equivalents THTX´s has?
What are THTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 460
Healthcare Sector # 949
Within the Market # 3713


trailing twelve months Quick Ratio Statistics
High Average Low
0.77 0.75 0.72
(Nov 30 2019)   (Nov 30 2023)




Companies with similar Quick Ratio in the quarter ending Nov 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioNov 30 2024 MRQ Cash & cash equivalentNov 30 2024 MRQ Current Liabilities
Arbutus Biopharma Corp  2.17 $ 36.386  Millions$ 16.782  Millions
Ultragenyx Pharmaceutical Inc   2.15 $ 610.025  Millions$ 284.009  Millions
Hutchmed china Limited  2.14 $ 837.191  Millions$ 391.267  Millions
Transcode Therapeutics Inc   2.14 $ 5.923  Millions$ 2.772  Millions
Decoy Therapeutics Inc   2.10 $ 2.435  Millions$ 1.159  Millions
Veru Inc   2.10 $ 24.916  Millions$ 11.868  Millions
Nuvectis Pharma inc   2.08 $ 18.533  Millions$ 8.894  Millions
Inmed Pharmaceuticals Inc  2.07 $ 3.541  Millions$ 1.708  Millions
Zevra Therapeutics Inc   2.04 $ 69.496  Millions$ 34.065  Millions
Immix Biopharma Inc   2.04 $ 17.682  Millions$ 8.687  Millions
Aptevo Therapeutics Inc   1.98 $ 8.714  Millions$ 4.396  Millions
Adagene Inc   1.97 $ 86.973  Millions$ 44.236  Millions
Ptc Therapeutics inc   1.96 $ 1,139.696  Millions$ 580.981  Millions
Protagenic Therapeutics Inc new  1.95 $ 1.838  Millions$ 0.943  Millions
Metavia Inc   1.94 $ 16.017  Millions$ 8.271  Millions
Jupiter Neurosciences Inc   1.92 $ 3.770  Millions$ 1.959  Millions
Arcutis Biotherapeutics Inc   1.91 $ 156.620  Millions$ 81.833  Millions
Telomir Pharmaceuticals Inc   1.86 $ 1.266  Millions$ 0.681  Millions
Purple Biotech Ltd  1.86 $ 7.401  Millions$ 3.987  Millions
Travere Therapeutics Inc   1.85 $ 370.701  Millions$ 200.751  Millions
Schrodinger Inc   1.84 $ 352.124  Millions$ 191.747  Millions
Biomarin Pharmaceutical Inc  1.83 $ 1,137.706  Millions$ 620.044  Millions
Altamira Therapeutics Ltd   1.81 $ 0.999  Millions$ 0.552  Millions
Medicus Pharma Ltd   1.81 $ 4.164  Millions$ 2.306  Millions
Allarity Therapeutics Inc   1.80 $ 19.533  Millions$ 10.839  Millions
2seventy Bio Inc   1.78 $ 71.244  Millions$ 40.092  Millions
Geovax Labs Inc   1.77 $ 5.507  Millions$ 3.107  Millions
Organogenesis Holdings Inc   1.75 $ 135.571  Millions$ 77.477  Millions
Indaptus Therapeutics Inc   1.75 $ 5.787  Millions$ 3.310  Millions
Acadia Pharmaceuticals Inc   1.74 $ 755.993  Millions$ 433.245  Millions

Date modified: 2026-09-02T18:17:12+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.